| HOME >> BIOLOGY >> TECHNOLOGY |
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".
For further information contact:
Investor & Media Relations
Ian Stone
Russo Partners LLC
Tel: (619) 814-3510
Fax: (619) 955-5318
Email: ian.stone@russopartnersllc.com
David Schull
Russo Partners LLC
Tel: (212) 845-4271
Email: david.schull@russopartnersllc.com
http://www.russopartnersllc.com
The Toronto and Frankfurt Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of this
News Release. Reported financial information may not necessarily be
indicative of future operating results or of future financial position, due
to a number of risks and uncertainties, including those set forth below.
This News Release contains certain forward-looking statements and
information regarding anticipated developments in the Company's business
and the sufficiency of the Company's cash reserves and expected cash flow
from operations, which statements and information can be identified by the
use of forward-looking terminology such as "to perform", "to develop", "in
preparation for", "in anticipation of", "to
'/>"/>
| SOURCE Helix BioPharma Corp. Copyright©2008 PR Newswire. All rights reserved |